Company Overview
Aligos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics designed to address unmet medical needs specifically within the domains of liver and viral diseases. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, where it pursues the advancement of its primary drug candidate, ALG-055009, which is currently undergoing Phase 2a clinical trials as a small molecule THR-ß agonist. In terms of operational scale, the entity employs 82 individuals and maintains a total market capitalization of $41.21M alongside reported annual revenue of $2.19M. These valuation and revenue figures indicate that Aligos Therapeutics holds a position as a small-cap biotechnology firm, suggesting that its market capitalization reflects a significant reliance on future clinical trial outcomes rather than established commercial cash flows, while the modest revenue base underscores the transitional nature of its business model prior to full commercialization.
Financial Health
The company reported revenue of $2.19M for the trailing twelve months, yet generated a net income of $-24,193,000, creating a substantial gap that reveals a highly leveraged cost structure where operational expenses vastly exceed income generation. This disparity is further highlighted by an EBITDA of $-87,055,000, indicating that the company is burning through resources at a rate that suggests heavy investment in research and development or clinical trial infrastructure. Free cash flow stands at $-50,040,624, which signifies a negative financial flexibility where the company is consuming cash reserves to fund its operations and development pipeline without current commercial revenue sufficiency. The financial margins present a challenging picture: a gross margin of 0.0% indicates that revenue does not cover the direct costs of production, while an operating margin of -12907.7% and a profit margin of 0.0% reflect deep losses relative to sales volume. On the balance sheet, the company holds $77.84M in cash against $5.25M in debt, resulting in a debt-to-equity ratio of 9.80, which classifies the entity as highly leveraged despite the nominal debt amount due to the small equity base. Liquidity is supported by a current ratio of 3.90, indicating that the company possesses sufficient current assets to cover its short-term liabilities nearly four times over. Return metrics show a return on equity of -196.9% and a return on assets of -69.3%, revealing that management effectiveness is currently measured in terms of value destruction per dollar of equity and assets due to the absence of profitability.
Valuation Assessment
The valuation metrics display a disconnect between historical and forward-looking expectations, with a trailing P/E ratio of N/A and a forward P/E of -1.25, implying that the market is pricing in the expectation of future earnings recovery rather than valuing current profitability. The price-to-book ratio is set at 0.77, which indicates that the company is trading below its book value, suggesting the market assigns a discount to the firm's tangible assets or anticipates significant dilution and risk in its asset base. Alternative valuation measures include a price-to-sales ratio of 18.85 and an EV/EBITDA of 0.36, which suggest that investors are willing to pay a premium relative to sales volume despite the lack of earnings, while the extremely low EV/EBITDA reflects the negative earnings multiple. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $13.69 and a 52-week low of $3.76. Relative to this range, the current price sits in a position that requires precise calculation against the high and low, but the wide spread demonstrates a stock with substantial potential for price movement based on clinical data releases or regulatory milestones. The beta value is recorded at 2.75, which means the stock's price volatility is significantly higher than the broader market, moving nearly three times as much as the general market index during periods of fluctuation.
Growth & Income
Growth metrics reveal a contraction in business scale with a revenue growth year-over-year of -73.1%, while earnings growth is listed as N/A due to the company's unprofitable status. The fact that revenue is declining indicates a shrinking top line, and since the company has no earnings to grow, the trajectory implies that the business is currently in a phase of contraction or repositioning rather than expansion. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, meaning that the firm reinvests its limited cash flow and retained earnings directly into its research and development activities rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion and zero dividend distribution, positioning the asset strictly as a speculative vehicle for capital appreciation driven by clinical trial success rather than a source of current income or stable revenue growth.